40 related articles for article (PubMed ID: 2138986)
1. Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation.
Tunn UW; Gruca D; Bacher P
Clin Interv Aging; 2013; 8():457-64. PubMed ID: 23637525
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard(®)/Depo-Eligard(®)) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study.
Braeckman J; Michielsen D
Arch Med Sci; 2014 Jun; 10(3):477-83. PubMed ID: 25097577
[TBL] [Abstract][Full Text] [Related]
3. Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release.
Kamaly N; Yameen B; Wu J; Farokhzad OC
Chem Rev; 2016 Feb; 116(4):2602-63. PubMed ID: 26854975
[TBL] [Abstract][Full Text] [Related]
4. Gonadotropin-releasing hormone stimulation test for precocious puberty.
Kim HK; Kee SJ; Seo JY; Yang EM; Chae HJ; Kim CJ
Korean J Lab Med; 2011 Oct; 31(4):244-9. PubMed ID: 22016677
[TBL] [Abstract][Full Text] [Related]
5. Utility of single luteinizing hormone determination 3 h after depot leuprolide in monitoring therapy of gonadotropin-dependent precocious puberty.
Acharya SV; Gopal RA; George J; Bandgar TR; Menon PS; Shah NS
Pituitary; 2009; 12(4):335-8. PubMed ID: 19396631
[TBL] [Abstract][Full Text] [Related]
6. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.
Plosker GL; Brogden RN
Drugs; 1994 Dec; 48(6):930-67. PubMed ID: 7533699
[TBL] [Abstract][Full Text] [Related]
7. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders.
Chrisp P; Sorkin EM
Drugs Aging; 1991; 1(6):487-509. PubMed ID: 1794035
[TBL] [Abstract][Full Text] [Related]
8. [Once-a-month injectable microcapsules of leuprorelin acetate].
Toguchi H; Ogawa Y; Okada H; Yamamoto M
Yakugaku Zasshi; 1991 Aug; 111(8):397-409. PubMed ID: 1795229
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of depot leuprorelin.
Periti P; Mazzei T; Mini E
Clin Pharmacokinet; 2002; 41(7):485-504. PubMed ID: 12083977
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical manipulation of leuprorelin acetate to improve clinical performance.
Toguchi H
J Int Med Res; 1990; 18 Suppl 1():35-41. PubMed ID: 2138986
[TBL] [Abstract][Full Text] [Related]
11. Formulation study of leuprorelin acetate to improve clinical performance.
Toguchi H
Clin Ther; 1992; 14 Suppl A():121-30. PubMed ID: 1606592
[TBL] [Abstract][Full Text] [Related]
12. Preliminary clinical evaluation of leuprorelin acetate depot injection in France, in the management of prostatic cancer.
Navratil H
J Int Med Res; 1990; 18 Suppl 1():69-73. PubMed ID: 2108887
[TBL] [Abstract][Full Text] [Related]
13. 3.75 and 7.5 mg leuprorelin acetate depot in the treatment of advanced prostatic cancer: preliminary report. German Leuprorelin Study Group.
Bischoff W
J Int Med Res; 1990; 18 Suppl 1():103-13. PubMed ID: 2108882
[TBL] [Abstract][Full Text] [Related]
14. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
Niijima T; Aso Y; Akaza H; Fujita K; Fuse H; Hosaka M; Isurugi K; Kamidono S; Katayama T; Kawabe K
Hinyokika Kiyo; 1990 Nov; 36(11):1343-60. PubMed ID: 2126912
[TBL] [Abstract][Full Text] [Related]
15. Leuprorelin acetate depot in advanced prostatic cancer: a phase II multicentre trial.
Rizzo M; Mazzei T; Mini E; Bartoletti R; Periti P
J Int Med Res; 1990; 18 Suppl 1():114-25. PubMed ID: 2108883
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]